Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LHRH Analogue Clear all
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 26, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Females, Aging, Metabolism, and Exercise

NCT01712230
View directory record Official record
Conditions
Obesity
Interventions
GnRH agonist, Supervised cardiovascular exercise, Placebo
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
View directory record Official record
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 26, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 26, 2026, 8:04 PM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

NCT00586898
View directory record Official record
Conditions
Prostate, Cancer, Hormonal Cycling
Interventions
GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 26, 2026, 8:04 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Adaptions and Resiliency to Multi-Stressor OpeRations

NCT06455969
View directory record Official record
Conditions
Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
Interventions
Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
Drug · Other
Lead sponsor
Bradley Nindl
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System Study

NCT00706784
View directory record Official record
Conditions
Healthy
Interventions
Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 26, 2026, 8:04 PM EDT
Not listed Phase 2 Interventional

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

NCT02689921
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Letrozole, Anastrozole, Leuprolide Acetate, Pertuzumab, Trastuzumab
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Newnan, Georgia • Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 26, 2026, 8:04 PM EDT
Terminated Phase 2 Interventional Results available

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

NCT00090844
View directory record Official record
Conditions
Breast Cancer, Hormone Changes, Drug Toxicity
Interventions
triptorelin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
Up to 44 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Oakland, California • Tampa, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 26, 2026, 8:04 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 8:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

NCT06001762
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions
Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)

NCT01223079
View directory record Official record
Conditions
Outcome During r-hFSH Stimulation, Outcome During r-hFSH and r-hLH Stimulation
Interventions
r-hFSH, r-hFSH and r-hLH
Drug
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
21 Years to 32 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 26, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

NCT05593497
View directory record Official record
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 26, 2026, 8:04 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 26, 2026, 8:04 PM EDT
Recruiting Phase 3 Interventional

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

NCT01492972
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Androgen Suppression Therapy
Radiation · Drug
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 26, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty

NCT00001181
View directory record Official record
Conditions
Polyostotic Fibrous Dysplasia, Precocious Puberty
Interventions
Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1982 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 8:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

NCT00001412
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 8:04 PM EDT
Active, not recruiting Phase 4 Interventional

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

NCT03016741
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 26, 2026, 8:04 PM EDT